




版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Adrenal Incidentaloma guidelines AACE/AAES OutlineDefinitionPrevalenceAnatomy and Physiology ReviewDiagnostic WorkupsConclusionsDefinition“Mass lesion greater than 1 cm in diameter discovered “accidentally” during a radiographic examination performed for indications other than an evaluation for adre
2、nal disease.”Management of the clinically inapparent adrenal mass (incidentaloma). NIH State-of-the-Science Conference Statement Feb 4-6, 2002.PrevalenceAutopsies: 87,065 cases: 6% with adrenal adenomasAbdominal CT (61,054 CT scans reviewed): 4% with adrenal adenomasNow approaches the 8.7% incidence
3、 reported in autopsy series Incidence Increases with AgeEndocrine and Metabolism Clinics of North America . 2000; 29(1):159-185Three Main QuestionsIs the adrenal mass hormonally active?Is the mass benign or malignant?Does the patient have a history of a previous malignant lesion?Is it metastatic?Ana
4、tomyhttp:/sealion/view_photo.php?set_albumName=album265&id=AdrenalAnatomyhttp:/sealion/view_photo.php?set_albumName=album265&id=AdrenalAnatomyPrimary AldosteronismCushings SyndromeDHEA-sPheochromocytomaFrequency of FindingsMulticenter study of 1096 casesNonfunctioning adenoma: 85%Subclinical Cushing
5、s syndrome: 9%Pheochromocytoma: 4%Aldosteronomas: 2%Mantero et al. 85 (2): 637. (2000) Frequency of FindingsAllolio, B., Adrenal Incidentalomas.Adrenal Disorders, ed. C.G. Margioris AN. 2001, Totowa: Humana Press Inc. A summary of the literatureNonfunctioning adenoma Approximately 80% Subclinical Cu
6、shing syndrome (SCS), 5%Pheochromocytoma 5%Aldosteronoma 1%adrenocortical carcinoma (ACC) 5 % Metastatic lesion 2.5%Ganglioneuromas, myelolipomas,or benign cysts考慮是否手術(shù)治療之前準(zhǔn)確的功能診斷非常必要 嗜鉻細(xì)胞瘤要進(jìn)行認(rèn)真的術(shù)前準(zhǔn)備以避免術(shù)中和術(shù)后的發(fā)作和死亡。原發(fā)性醛固酮增多癥的患者需要明確是否存在腎上腺皮質(zhì)增生及無(wú)功能的腎上腺腺瘤。腎上腺源性Cushing綜合征的患者在行切除術(shù)后可能發(fā)生腎上腺皮質(zhì)功能不全,激素的替代以及增減治療
7、需要非常仔細(xì)。亞臨床Cushing綜合征的患者是否需要手術(shù)治療仍存在爭(zhēng)議。腎上腺皮質(zhì)癌的患者手術(shù)前需要外科醫(yī)師和內(nèi)分泌科醫(yī)師或腫瘤科醫(yī)師共同協(xié)商決定切除的方式,因?yàn)槭状吻谐男Ч巧媛实闹饕A(yù)測(cè)因素。超過(guò)4cm的腎上腺無(wú)功能瘤可以考慮切除。小的髓脂肪瘤或良性的囊腫一般影像學(xué)檢查即可確診,通常不需要治療,除非有癥狀可以考慮手術(shù)治療。 Algorithm for the evaluation and management of an adrenal incidentaloma*Reimage in 3 to 6 months and annually for 1 to 2 years; repe
8、at functional studies annually for 5 years.If mass grows more than 1cm or becomes hormonally active, then adrenalectomy is recommended.Hyperfunctioning Hormonal EvaluationSubclinical Cushings SyndromePheochromocytomaPrimary AldosteronismSex hormone-secreting adrenocortical tumorsSubclinical Cushings
9、 SyndromeHypercortisolism without clinical manifestations of Cushings syndrome Most frequent hormonal abnormality in adrenal incidentalomas Subclinical Cushings SyndromeCentral obesityFacial roundingBuffalo humpEasy bruisingPurple striaeProximal muscle weaknessEmotional/cognitive changesSubclinical
10、Cushings SyndromeIncrease risk for:HypertensionDyslipidemiaImpaired glucose tolerance Type 2 DMAtherosclerosisOsteoporosis?Tauchmanova L, et. al. Patients with subclinical Cushings syndrome due to adrenal adenoma have increase cardiovascular risk. JCEM 2000; 85:1440.Subclinical Cushings SyndromeBioc
11、hemical abnormalitiesElevated urine free cortisolLow or suppressed ACTH Blunted diurnal variation No cortisol suppression after 1 mg overnight dexamethasone suppression test- BEST SCREENING TEST!1. Mantero F, et al. Hormone Res 47:284289, 19972. Montwill J, et al. The O/N DST is the procedure of cho
12、ice for screening for Cushings syndrome. Steroids 1994; 59:2296Dexamethasone Suppression Test1 mg dexamethasone at 11PMMeasure cortisol at 8 AM the next morningNormal: cortisol 30 and PAC 20 ng/dL90% spec and sensitivity for PAIf screening test is positive- need to confirm with saline suppression te
13、st, adrenal venous sampling and imagingmidnight salivary cortisol, or a 2-day low-dose dexamethasone suppression testmidnight salivary cortisol, or a 2-day low-dose dexamethasone suppression testHyperfunctioning Hormonal EvaluationSubclinical Cushings SyndromePheochromocytomaPrimary AldosteronismSex
14、 hormone-secreting adrenocortical tumorsSex hormone-secreting Adrenocortical TumorsRareTypically occur in the presence of clinical manifestations (hirsutism or virilization)HirsutismSex hormone-secreting Adrenocortical TumorsRareTypically occur in the presence of clinical manifestations (hirsutism o
15、r virilization)Routine screening for excess androgens and estrogens is not warrantedHormonal Workup Summary3 hormonal tests necessary for workup of adrenal incidentaloma:1 mg overnight dexamethasone suppresion testPlasma or urinary fractionated metaneprinesPlasma aldosterone concentration and plasma
16、 aldosterone concentration/plasma renin activity ratio (PAC/PRA).TreatmentAll patients with documented pheochromocytoma and primary aldosteronism should undergo surgeryNo prospective, randomized trials for Subclinical Cushings Syndrome but concensus is to proceed with surgery if the patient is young
17、Three Main QuestionsIs the adrenal mass hormonally active?Is the mass benign or malignant?Does the patient have a history of a previous malignant lesion?Is it metastatic?Primary Adrenal CarcinomaVery rare: 5 cases per 1 million populationSmall size corresponds to better prognosis5 year survivalOvera
18、ll: 16%Localized disease (stage I and II): 42%Metastases: 5.3%Imagingcomplex solid and cystic, calcified massPatient with Known Malignancy10-40% of patients with known malignancy have adrenal metastases at autopsyMost common primaryBreastLungKidneyMelanomaLymphomaAssessment of Malignant PotentialSiz
19、eImaging Phenotype (features)SizeProbability of malignancy increases with sizeIn a study involving 887 patients with adrenal incidentalomas, 90% of patients with adrenal carcinomas has tumor 4 cm (National Italian Study Group, 1997)adrenal carcinomas 2%(6cm)SizeMayo Clinic Study342 Patients with adr
20、enal incidentaloma retrospectively evaluatedTumor diameter averaged 2.5 cmMost malignant tumors measured 5 cmIncidentally discovered adrenal tumors: an institutional perspective. Herrera MF; Grant CS; van Heerden JA; Sheedy PF; Ilstrup DM. Surgery 1991 Dec;110(6):1014-21 SizeConsensus StatementMass
21、6 cm should be removedMass 4 cm can be monitoredMass between 4-6 cm: Criteria other than size should be used to dictate surgery vs. monitoringManagement of the clinically inapparent adrenal mass (incidentaloma). NIH State-of-the-Science Conference Statement Feb 4-6, 2002.Assessment of Malignant Pote
22、ntialSizeImaging PhenotypeImage Phenotype- CT ScanHounsfield unit (HU)- semiquantitative method for measuring x-ray attenuationWater= 0 HUAdipose tissue= -20 to -150 HUKidney= 20 to 50 HUBone= 1000 HULipid rich mass are benignHU10 on unenhanced CT= benign adenoma 100%Image Phenotype- CT ScanRetrospe
23、ctive analysis of 151 patients with adrenal massesHU10 or a combination of tumor size 4cm and HU 60% at 10 min= no cancerWash out 60% at 10 min= high risk for malignant lesionImaging- metastasesMRIEqually effective as CTAdenomas are isointense with the liver on T2 weighted imagesCarcinomas are hyperintense compared to the liver on T2 weighted imagesFNACytology from FNA cannot distinguish benign adrenal mass vs. malignantIt can distinguish adrenal tissue from metastasesFNA is useful only in distinguishing
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 電子商務(wù)平臺(tái)對(duì)流通企業(yè)銷售模式的創(chuàng)新與影響
- 促進(jìn)養(yǎng)老服務(wù)消費(fèi)的金融產(chǎn)品與支付方式創(chuàng)新
- 2025至2030家禽飼養(yǎng)行業(yè)發(fā)展趨勢(shì)分析與未來(lái)投資戰(zhàn)略咨詢研究報(bào)告
- 海南省??谑忻?025屆九上化學(xué)期末聯(lián)考模擬試題含解析
- 黑龍江省大慶市杜爾伯特縣2025屆物理八年級(jí)第一學(xué)期期末質(zhì)量跟蹤監(jiān)視模擬試題含解析
- 寧夏石嘴山市星海中學(xué)2025屆物理八上期末教學(xué)質(zhì)量檢測(cè)試題含解析
- 江蘇省鹽城市亭湖初級(jí)中學(xué)2024年數(shù)學(xué)七上期末調(diào)研模擬試題含解析
- 電商平臺(tái)代理記賬與電商稅收政策合同
- 綠茶連鎖加盟總經(jīng)銷商協(xié)議書(shū)
- 2025年交管12123駕照學(xué)法減分題庫(kù)附含參考答案
- 2024年中國(guó)高純鉑族金屬行業(yè)調(diào)查報(bào)告
- 2025輔警招聘公安基礎(chǔ)知識(shí)考試題庫(kù)及答案
- 2025年銀行反洗錢知識(shí)競(jìng)賽考試卷庫(kù)90題
- DeepSeek在教育和學(xué)術(shù)領(lǐng)域的應(yīng)用場(chǎng)景與案例(上中下合集)
- 第10課+影響世界的工業(yè)革命+課件-2024-2025學(xué)年高一下學(xué)期統(tǒng)編版(2019)必修中外歷史綱要下
- DB41∕T 2741-2024 高速公路聯(lián)網(wǎng)收費(fèi)系統(tǒng)養(yǎng)護(hù)技術(shù)規(guī)范
- 2025基層法律服務(wù)試題及答案
- 2024年上海市教育評(píng)估院招聘筆試真題
- 暗夜旅游地光污染治理-洞察及研究
- 護(hù)士職業(yè)損傷防護(hù)課件
- 2025汽車貸款還款合同范本
評(píng)論
0/150
提交評(píng)論